These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 21596683)

  • 1. On a different level: telavancin versus vancomycin for hospital-acquired pneumonia.
    Tarchini G
    Clin Infect Dis; 2011 Jun; 52(11):1390; author reply 1391-2. PubMed ID: 21596683
    [No Abstract]   [Full Text] [Related]  

  • 2. Pharmacodynamics, pharmacokinetics and clinical efficacy of telavancin in the treatment of pneumonia.
    Adamantia L; Antoni T
    Expert Opin Drug Metab Toxicol; 2016 Jul; 12(7):803-12. PubMed ID: 27158752
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Telavancin versus vancomycin for bacteraemic hospital-acquired pneumonia.
    Stryjewski ME; Barriere SL; Rubinstein E; Genter FC; Lentnek AL; Magana-Aquino M; Luna CM; Niederman MS; Torres A; Corey GR
    Int J Antimicrob Agents; 2013 Oct; 42(4):367-9. PubMed ID: 23891527
    [No Abstract]   [Full Text] [Related]  

  • 4. Telavancin hospital-acquired pneumonia trials: impact of Gram-negative infections and inadequate Gram-negative coverage on clinical efficacy and all-cause mortality.
    Lacy MK; Stryjewski ME; Wang W; Hardin TC; Nogid B; Luke DR; Shorr AF; Corey GR; Barriere SL
    Clin Infect Dis; 2015 Sep; 61 Suppl 2():S87-93. PubMed ID: 26316562
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Telavancin for the treatment of hospital-acquired pneumonia: findings from the ATTAIN studies.
    Nannini EC; Corey GR; Stryjewski ME
    Expert Rev Anti Infect Ther; 2012 Aug; 10(8):847-54. PubMed ID: 23030322
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The ATTAIN trials: efficacy and safety of telavancin compared with vancomycin for the treatment of hospital-acquired and ventilator-associated bacterial pneumonia.
    Barriere SL
    Future Microbiol; 2014; 9(3):281-9. PubMed ID: 24450506
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The clinical positioning of telavancin in Europe.
    Masterton R; Cornaglia G; Courvalin P; Lode HM; Rello J; Torres A
    Int J Antimicrob Agents; 2015 Mar; 45(3):213-20. PubMed ID: 25600892
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Telavancin versus vancomycin for hospital-acquired pneumonia due to gram-positive pathogens.
    Rubinstein E; Lalani T; Corey GR; Kanafani ZA; Nannini EC; Rocha MG; Rahav G; Niederman MS; Kollef MH; Shorr AF; Lee PC; Lentnek AL; Luna CM; Fagon JY; Torres A; Kitt MM; Genter FC; Barriere SL; Friedland HD; Stryjewski ME;
    Clin Infect Dis; 2011 Jan; 52(1):31-40. PubMed ID: 21148517
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The role of telavancin in hospital-acquired pneumonia and ventilator-associated pneumonia.
    Sandrock CE; Shorr AF
    Clin Infect Dis; 2015 Sep; 61 Suppl 2():S79-86. PubMed ID: 26316561
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Telavancin (Vibativ) for gram-positive skin infections.
    Med Lett Drugs Ther; 2010 Jan; 52(1329):1-2. PubMed ID: 20208468
    [No Abstract]   [Full Text] [Related]  

  • 11. Baseline activity of telavancin against Gram-positive clinical isolates responsible for documented infections in U.S. hospitals (2011-2012) as determined by the revised susceptibility testing method.
    Mendes RE; Farrell DJ; Sader HS; Flamm RK; Jones RN
    Antimicrob Agents Chemother; 2015 Jan; 59(1):702-6. PubMed ID: 25348529
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association of the clinical efficacy of vancomycin with the novel pharmacokinetic parameter area under the trough level (AUTL) in elderly patients with hospital-acquired pneumonia.
    Fukumori S; Tsuji Y; Mizoguchi A; Kasai H; Ishibashi T; Iwamura N; To H
    J Clin Pharm Ther; 2016 Aug; 41(4):399-402. PubMed ID: 27144370
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Telavancin for the treatment of serious gram-positive infections, including hospital acquired pneumonia.
    Rubinstein E; Corey GR; Stryjewski ME; Kanafani ZA
    Expert Opin Pharmacother; 2011 Dec; 12(17):2737-50. PubMed ID: 22077833
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Telavancin (Vibativ). A vancomycin derivative, no more effective but more toxic.
    Prescrire Int; 2015 Nov; 24(165):257-9. PubMed ID: 26688891
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Telavancin: a lipoglycopeptide antimicrobial for the treatment of complicated skin and skin structure infections caused by gram-positive bacteria in adults.
    Chang MH; Kish TD; Fung HB
    Clin Ther; 2010 Dec; 32(13):2160-85. PubMed ID: 21316534
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A comparative review of the lipoglycopeptides: oritavancin, dalbavancin, and telavancin.
    Guskey MT; Tsuji BT
    Pharmacotherapy; 2010 Jan; 30(1):80-94. PubMed ID: 20030476
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Linezolid for the treatment of infections caused by Gram-positive pathogens in China.
    Lin DF; Zhang YY; Wu JF; Wang F; Zheng JC; Miao JZ; Zheng LY; Sheng RY; Zhou X; Shen HH; Ijzerman MM; Croos-Dabrera RV; Sheng W
    Int J Antimicrob Agents; 2008 Sep; 32(3):241-9. PubMed ID: 18635341
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Telavancin versus standard therapy for treatment of complicated skin and soft-tissue infections due to gram-positive bacteria.
    Stryjewski ME; O'Riordan WD; Lau WK; Pien FD; Dunbar LM; Vallee M; Fowler VG; Chu VH; Spencer E; Barriere SL; Kitt MM; Cabell CH; Corey GR;
    Clin Infect Dis; 2005 Jun; 40(11):1601-7. PubMed ID: 15889357
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Telavancin: a new lipoglycopeptide for gram-positive infections.
    Smith WJ; Drew RH
    Drugs Today (Barc); 2009 Mar; 45(3):159-73. PubMed ID: 19436839
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vancomycin-resistant enterococci.
    Rubinstein E; Keynan Y
    Crit Care Clin; 2013 Oct; 29(4):841-52. PubMed ID: 24094380
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.